Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I was under the impression P1a / P1b was a fluid trial same as a 2a / 2b trial, as in if you you stop after P1a for any reason e.g. lack of funds or other reason then you cant restart a P1b at a later date and the only remaining option is a P2a.
Hi Pot, the Bod has led us down the path that potential partners need some proof of efficacy not only for a license deal but for shareholder value so if we are looking to license at the end of P1a now that would mean a smaller upfront compared to showing some efficacy in a P1b. So why change path now when we are only £500k short of the original RF full £5m drawdown and the advantages of continuing with the P1b in Aus, tax credits etc….
Thanks for the link HBD good to read over the Edison report again, it comes across if data & safety are good then it's a wait and see if we can get a partner license deal otherwise it's more dilution, also moot point on P2a over 1b Edison does not differentiate and it's just down to wait and see. Feels like we are in a sidewards holding position when before we would have finished P1b this year....
Hi HBD, at the moment the bod haven't directly stated why the change of direction so just looking at possible reasons why the decision was made for a 2a and have taken your points onboard and not forgetting this is a double blinded trial and as such the Bod are also blind to full data.
It could have been a purely financial decision, maybe they feel they need to dose higher and a 2a would be more expandable/ suitable to see some efficacy, maybe they want some breathing space to see if a licence deal emerges or maybe they just haven't got a clue what and are just bouncing from pillar to post.
As always we will be the last to find out hopefully all will be revealed and news soon...
Colbalt there remains way to many unknowns and variables, will we get a Mad finish RNS or are we to wait until the end of June for full data, no guarantees that will be positive enough to move forwards, market has no idea if we can fund a P2a, market has no idea what’s happening with SRA737…..
"The multiple ascending dose (MAD) portion of SDC-1801 is nearing completion. Sareum aims to conclude this part of the trial by the end of Q2 2024. Subject to data review, additional funding and/or potential licencing opportunities, we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024."
Well the SP was pretty stable from Aug through Jan before the 3rd drawdown so makes no sense, but either way they are gone now still don't think it was the worst option at least we were funded for P1b and weren't diluted further....
Pot not defending the Bod and they should of raised on previous highs for P1a / P1b but possible it was the only option available at the time, didn't the RF deal fail because of low volume which was just market sentiment....
To be fair it was a tough call which way the SP was going after the last week's increases, good to see RF nearly cleared now that news is most likely priced in as markets know it's coming before the end of the month. Trial end Mad premilinary should add support then its all eyes on the Full P1a now end of Q2 GLA
Sad agreed so they will start forward selling todays 3m into next week and get a final tranche of around 2.5m so 5.5m to clear effectively giving them the last 2.5m free & the warrants free, not a bad business for them hey /
Maths post made sense that they are still getting the shares at 0.095p just under the placing price on the lowest 15 day VWAP so they are actually making some decent returns, would not be at all surprised if they are giving the SP a bit of a nudge.... Thank F**k they will be cleared for good soon.